In response to the Millennium Development Goals, and now to the Sustainable Development Goals defined by the United Nations, bioMérieux is focusing its efforts on HIV/AIDS, tuberculosis and malaria, drawing upon its expertise in infectious diseases.
In addition to these primary objectives, bioMérieux also develops diagnostic solutions to address other public health challenges, such as testing for emerging viruses.
Our goal is to give access to biological diagnostic techniques in developing countries leveraging our presence in over 150 countries worldwide through 42 subsidiaries and a network of distributors. In concrete terms, we participate in healthcare programs receiving the support of important donors*, large international organizations** or NGOs, aiming to make diagnostic tools available locally, train personnel in the utilization of these systems and ensure post-installation follow-up.
* Global Fund, World Bank, UNITAID, etc.
** WHO, Unicef, PAHO, etc.
Our Key Assets
- Our global presence, including limited resource countries. Our teams in the field provide assistance for lab installation, technical training as well as local follow-up for users.
- Our historical expertise and commitment in the field of infectious diseases allow us to provide diagnostic solutions of excellent quality in formats that meet the needs of different healthcare settings.
- Within the framework of its sponsorship activities, bioMérieux supports the work of the Fondation Mérieux and the Fondation Christophe et Rodolphe Mérieux. These two independant family foundations focus on the fight against infectious diseases that affect developing countries by building capacities, particularly in the field of diagnostics.
Innovation of the year at the Africa Healthcare Summit
In February 2016, bioMérieux received the Innovation of the Year Award in the category “Technology and Solution Providers Operating in Africa and/or Exporting to Africa”, conferred by a panel of experts during the third edition of the Africa Healthcare Summit. This award recognizes the value of bioMérieux diagnostic solutions to address needs in developing countries, in particular with the rapid tests VIKIA® HBs Ag, VIKIA® HIV 1/2, the NucliSENS EasyQ® HIV-1 (which measures HIV-1 viral load) and the FilmArray® BioThreat-E test™ for Ebola virus detection.